What is GenrAb?
GenrAb is a biotechnology firm dedicated to pioneering neuroprotective therapies by leveraging the human immune system. The company employs its proprietary Antibody Gene Signature technology to identify fully-human monoclonal antibodies with therapeutic potential. Its lead candidate, TGM-010, is designed to halt disease progression and improve patient outcomes in various neurodegenerative disorders. GenrAb's mission extends beyond scientific advancement to fundamentally transforming neurological care and enhancing the quality of life for patients.
How much funding has GenrAb raised?
GenrAb has raised a total of $5.6M across 1 funding round:
Angel/Seed
$5.6M
Angel/Seed (2025): $5.6M with participation from Actium Group
Key Investors in GenrAb
Actium Group
Actium Group is a consulting firm focused on identifying growth opportunities and providing comprehensive project planning and cost analysis. They partner selectively with clients, offering personalized guidance to drive success and profitability.
What's next for GenrAb?
The substantial enterprise-level funding and strategic investment signal a critical growth phase for GenrAb. This capital infusion is expected to accelerate the clinical development of TGM-010 and potentially expand the company's research pipeline. GenrAb is poised to further validate its Antibody Gene Signature technology and solidify its position as a leader in developing innovative treatments for neurological diseases, aiming to bring impactful therapies to market and address unmet patient needs.
See full GenrAb company page
